⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cytosine SCHEMBL29787229 | 1.00 | POLB (0.42) | — | |
| Cytosine SCHEMBL9116352 | 0.98 | POLB (0.41) | — | |
| Adenine SCHEMBL30068984 | 0.76 | PI4KA (0.63) | — | |
| SCHEMBL4795553 | 0.75 | — | — | |
| Guanine SCHEMBL29349830 | 0.74 | PNP (0.72) | — | |
| SCHEMBL2927541 | 0.72 | — | — | |
| SCHEMBL21792155 | 0.70 | — | — | |
| SCHEMBL29029023 | 0.70 | — | — | |
| Uracil SCHEMBL29525634 | 0.70 | — | — | |
| SCHEMBL30315297 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 466 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1648874-B1 | PIPERAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC (CA) | 2011-10-05 | — | — | EP | claimed |
| EP-1846035-B1 | COMBINATION THERAPY | XENON PHARMACEUTICALS INC (CA) | 2011-09-21 | — | — | EP | claimed |
| US-20100056460-A1 | COMBINATION OF ORGANIC COMPOUNDS | ALI MOHAMMED A | 2010-03-04 | — | — | US | claimed |
| US-20090131447-A1 | COMBINATION THERAPY | XENON PHARMACEUTICALS INC. (CA) | 2009-05-21 | — | — | US | claimed |
| CN-101203244-A | Compositions of rennin inhibitor and insulin secernent or insulin sensitizer | NOVARTIS AG (CH) | 2008-06-18 | — | — | CN | claimed |
| CN-101163504-A | Combination therapy | XENON PHARMACEUTICALS INC (CA) | 2008-04-16 | — | — | CN | claimed |
| EP-1907004-A2 | COMBINATION OF A RENIN INHIBITOR AND AN INSULIN SECRETION ENHANCER OR AN INSULIN SENSITIZER | Novartis AG (CH) | 2008-04-09 | — | — | EP | claimed |
| US-7335658-B2 | Pyridazine derivatives and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2008-02-26 | — | — | US | claimed |
| EP-1846035-A2 | COMBINATION THERAPY | XENON PHARMACEUTICALS INC. (CA) | 2007-10-24 | — | — | EP | claimed |
| WO-2007005763-A2 | COMBINATION OF A RENIN INHIBITOR AND AN INSULIN SECRETION ENHANCER OR AN INSULIN SENSITIZER | NOVARTIS AG (CH) | 2007-01-11 | — | — | WO | claimed |
| WO-2006086445-A2 | COMBINATION THERAPY | XENON PHARMACEUTICALS INC. (CA) | 2006-08-17 | — | — | WO | claimed |
| US-20050065143-A1 | Pyridazine derivatives and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2005-03-24 | — | — | US | claimed |
| US-20260130997-A1 | METHODS AND COMPOSITIONS FOR ANTI-CD45 BASED NON-GENOTOXIC CONDITIONING | BEAM THERAPEUTICS INC. (US) | 2026-05-14 | — | — | US | disclosed |
| US-20260117176-A1 | MODIFIED IMMUNE EFFECTOR CELLS WITH IMPROVED EFFICACY | BEAM THERAPEUTICS INC. (US) | 2026-04-30 | — | — | US | disclosed |
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | ERESINA LLC (US) | 2026-04-16 | — | — | US | disclosed |
| EP-4713005-A2 | METHODS AND COMPOSITIONS FOR ANTI-CD45 BASED NON-GENOTOXIC CONDITIONING | Beam Therapeutics Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| WO-2001095910-A1 | IMIDAZOPYRIDINE AND IMIDAZOPYRIMIDINE ANTIVIRAL AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-12-20 | — | — | WO | disclosed |
| EP-1098644-A1 | SUBSTITUTED BENZIMIDAZOLE ANTIVIRAL AGENTS | Bristol-Myers Squibb Company (US) | 2001-05-16 | — | — | EP | disclosed |
| WO-2000004900-A1 | SUBSTITUTED BENZIMIDAZOLE ANTIVIRAL AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-02-03 | — | — | WO | disclosed |
| US-4301196-A | USING ACCELERATING OR DEPOLARIZING AGENTS WHICH ARE ORGANONITROGEN COMBOUNDS | KOLLMORGEN TECHNOLOGIES CORP. (US) | 1981-11-17 | — | — | US | disclosed |